SPRUCE BIOSCIENCES, INC.
For the period ended Sep 30, 2026. Filed Nov 9, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unregistered Sales of Equity Securities and Use of Proceeds
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Unregistered Sales of Equity Securities
On August 7, 2026, we entered into a Stock Purchase Agreement with the National MPS Society and the Cure Sanfilippo Foundation, pursuant to which we agreed to sell and issue 121,203 shares of our common stock at a purchase price of $45.38 per share, for gross proceeds of $5.5 million, in a private placement that closed in August 2026. The shares were offered and sold in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D promulgated thereunder.
Issuer Purchases of Equity Securities
None.
Working Capital Restrictions and Limitations Upon the Payment of Dividends
Pursuant to the Avenue Loan Agreement, we are prohibited from paying cash dividends without the prior written consent of Avenue.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.